Eli Lilly and Company

lilly.com

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

2,061

Active

226

Phase 3

547

Total enrollment

1,126,085

Pipeline matrix

Showing 40 of 194 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Tirzepatide73
Mirikizumab24
Pirtobrutinib16
Lebrikizumab17
Idelalisib1
Antihyperglycemic medication1
Abemaciclib53
Orforglipron30
Retatrutide19
Pembrolizumab20
Cisplatin82
Carboplatin58
Fulvestrant15
Donanemab13
Gemcitabine99
LY35370319
Anastrozole9
Eloralintide9
Brenipatide7
Baricitinib51
Letrozole8
Imlunestrant8
Exemestane6
Pemetrexed109
Tamoxifen7
Selpercatinib16
Topical corticosteroid6
Ramucirumab49
Paclitaxel37
Dulaglutide35
Ixekizumab29
Galcanezumab18
Adalimumab7
Bevacizumab14
Erlotinib11
LY35379828
Semaglutide7
Durvalumab5
Topotecan2
Lepodisiran2
154 more active programs hidden

Next readouts

  • 2015-03-20
  • 2017-01-31
  • 2017-02-14
  • 2017-09-15
  • 2018-02-16
  • 2018-06-15
  • 2019-01-23
  • 2019-03-29
  • 2020-02-03
  • 2020-02-27

Top conditions

  • Healthy286
  • Diabetes Mellitus, Type 2124
  • Healthy Volunteers85
  • Obesity84
  • Overweight62
  • Type 2 Diabetes54
  • Diabetes Mellitus, Type 145
  • Breast Cancer44

Frequently asked questions about Eli Lilly and Company

How many clinical trials does Eli Lilly and Company have on ClinicalTrials.gov?
Eli Lilly and Company is listed as the lead sponsor on 2,061 clinical trials in ClinicalTrials.gov, 226 of which are currently active (recruiting, enrolling, or ongoing).
How many of Eli Lilly and Company's trials are in Phase 3?
547 of Eli Lilly and Company's trials are in Phase 3, spread across 194 active drug programs.
What therapeutic areas does Eli Lilly and Company focus on?
Eli Lilly and Company's most-studied conditions on ClinicalTrials.gov are Healthy, Diabetes Mellitus, Type 2, Healthy Volunteers, Obesity, Overweight.
When are Eli Lilly and Company's next clinical trial readouts?
Eli Lilly and Company has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study of LY2784544 in Participants With Myeloproliferative Neoplasms”, expected around 2015-03-20.